Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Earnings Data
Report Date
May 11, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.81Last Year’s EPS
-1.13Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: multiple registrational trials, regulatory designations (Breakthrough Therapy and a commissioner priority voucher), promising early clinical data (notably zoldonrasib combination responses), new compounds entering the clinic, and a solid cash position supplemented by a large Royalty Pharma commitment. Offsetting these positives are substantially higher R&D and G&A spending, a materially wider net loss, and elevated 2026 operating expense guidance as the company scales clinical and commercial activities. Clinical uncertainties remain (OS-driven readout timing, potential crossover risk, and difficult CRC biology), but the balance of progress and funding to execute the plan led management to accelerate investments. Overall, progress and available capital appear to outweigh the near-term financial drag from higher expenses.Company Guidance
Strong cash position and committed capital
Cash and investments of $2.03 billion at 12/31/2025 and access to up to $2.0 billion in committed capital via the Royalty Pharma agreement (first tranche of $250 million received; $1.75 billion remaining).
Robust late-stage clinical footprint
Eight ongoing or planned Phase III registrational trials across indications (pancreatic cancer, non-small cell lung cancer, colorectal cancer); more than 2,500 patients have received one or more RAS(ON) inhibitors in aggregate.
RASolute 302 enrollment complete; readout timing
Global enrollment for RASolute 302 (second-line metastatic pancreatic cancer) is complete with an anticipated readout in the first half of 2026 (OS event-driven).
Encouraging zoldonrasib first-line pancreatic combination data
Initial data for zoldonrasib + modified FOLFIRINOX in first-line metastatic pancreatic cancer showed a 63% partial response rate (confirmed or pending confirmation) and a disease control rate of 95%; high drug dose intensity maintained and majority of patients remained on treatment.
Regulatory recognition for key assets
Daraxonrasib received U.S. FDA Breakthrough Therapy designation and a commissioner national priority voucher (CMPV); zoldonrasib was awarded Breakthrough Therapy designation (company stated this is the third RAS(ON) inhibitor to receive this distinction).
Pipeline expansion and new clinical entrants
Four clinical-stage RAS(ON) investigational drugs highlighted (daraxonrasib, elironrasib, zoldonrasib, RMC-5127); RMC-5127 (G12V selective) first patient dosed in a first-in-human trial with expected recommended Phase II monotherapy dose in H2 2026. Preclinical RM-055 class showed deep, durable regressions in daraxonrasib-resistant models and the company plans to begin clinical development later in 2026.
Active external collaborations
Clinical collaborations in place with Tango Therapeutics, Bristol-Myers Squibb and Summit Therapeutics (e.g., combos with PRMT5 inhibitors and Ivonescimab PD-1/VEGF bispecific); first patient dosed in Summit combination trial.
Commercial and organizational readiness
Company is building a global commercial organization focused on an initial U.S. launch: key strategic hires, regional field sales leadership onboarded, and active recruitment for the first field sales team.
RVMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RVMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $103.24 | $102.15 | -1.06% |
Nov 05, 2025 | $59.34 | $61.38 | +3.44% |
Aug 06, 2025 | $36.67 | $34.95 | -4.69% |
May 07, 2025 | $37.66 | $41.91 | +11.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Revolution Medicines (RVMD) report earnings?
Revolution Medicines (RVMD) is schdueled to report earning on May 11, 2026, After Close (Confirmed).
What is Revolution Medicines (RVMD) earnings time?
Revolution Medicines (RVMD) earnings time is at May 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RVMD EPS forecast?
RVMD EPS forecast for the fiscal quarter 2026 (Q1) is -1.81.
